

Xbrane Biopharma - A bright future

Redeye raises its valuation on Xbrane following the positive outcome of its phase III study Xplore. Development is the core of Xbrane's strategy, and the company's biosimilar development approach has now received validation.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Xbrane Biopharma - A bright future